Episode Details
Back to Episodes
Bioretec Q4'25: Commercialization groundwork in progress
Published 1 month ago
Description
Bioretec has been rebuilding its commercial foundation during 2025 and is seeking to restore damaged investor confidence. To finance its growth strategy, the company announced it is considering a 15 MEUR share issue. Bioretec's CEO Sarah Hubar-Fisher in an interview with analyst Antti Siltanen.
Topics:
00:00 Introduction
00:15 Bioretec’s year 2025
00:45 Main reasons for stalled growth
02:21 The commercial progress of RemeOs
03:26 Situation in China
04:30 Chances in go-to-market strategy
05:22 Most important things to achieve in the US this year
06:40 Outlook for broadening the portfolio and expanding indications
07:47 Situation in Europe
08:51 Finnish hospitals
09:28 Partnership possibilities
10:38 KPI reporting
12:59 Plans regarding funding